Click to Share
 
 
  1. Latest News
  2. Submit Press Release

napsr Press Releases

  + XML/RSS  



By NAPSRx
Horizon Pharma plc has announced that ACTIMMUNE® has been granted Fast Track designation from the U.S. Food and Drug Administration (FDA), to treat Friedreich's ataxia (FA), a degenerative neuro-muscular disorder.
By NAPSRx
The U.S. Food and Drug Administration (FDA) has officially greenlighted Regeneron’s EYLEA® (aflibercept) Injection to treat Diabetic Retinopathy in Patients with Diabetic Macular Edema (DME) which marks the fourth approved indication for the drug in...
By NAPSRx
Eli Lilly has entered into an exclusive license agreement with Hanmi Pharmaceutical Co., Ltd. to develop and commercialize Hanmi's oral Bruton's tyrosine kinase (BTK) inhibitor, HM71224, for the treatment of autoimmune and other diseases.
By NAPSRx
In an effort to expand their presence in the oncology market and expand their already resilient pipeline, Abbvie will acquire Pharmacyclics  including its blockbuster product Imbruvica, a first class BTK inhibitor approved for hematologic...
By NAPSRx
The U.S. Food and Drug Administration (FDA) has approved Sanofi’s Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, intended to improve the glycemic index in adults living with type 1 and type 2...
By NAPSRx
The US Food and Drug Administration (FDA) has approved Novartis’ new psoriasis treatment Cosentyx (secukinumab) for adult patients who are candidates for systemic therapy (a drug that is absorbed into the bloodstream and distributed to all parts of the...
By NAPSRx
SAVAYSA™ (edoxaban) tablets, an oral once-daily selective factor Xa-inhibitor have been approved by the U.S.
By NAPSRx
The U.S Food and Drug Administration has greenlighted Novo Nordisk’s new drug application (NDA) for Saxenda®  a once daily once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for adults who are obese (BMI ≥30 kg/m2) or who are...
By NAPSRx
A new bill has been presented by U.S. Senators Michael Bennet (D-CO) and Orrin Hatch (R-UT)  to develop a new pathway for antibiotic drug approvals called the Promise for Antibiotics and Therapeutics for Health (PATH) Act .This act is anticipated to.
By NAPSRx
Eli Lilly will obtain an exclusive worldwide license from Zosano Pharma Corporation to commercialize their investigational therapy ZP-PTH intended to treat osteoporosis patients.
By NAPSRx
AstraZeneca and Eli Lilly and Company have recruited their first patient for the AMARANTH Phase II/III study to assess an oral beta secretase cleaving enzyme (BACE) inhibitor called AZD3293 which is currently being developed as a treatment option for...
By NAPSRx
According to the Decisions Resource Group sales of migraine therapies are projected to grow from $3 billion to over $5 billion in the United States, France, Germany, Italy, Spain, United Kingdom and Japan through 2023.
By NAPSRx
AstraZeneca plans to invest up to $200 million to increase manufacturing and production efforts at its biologics manufacturing center in Frederick, Maryland, US.
By NAPSRx
Sanofi and Regeneron’s investigational therapy, Dupilumab has received the Breakthrough Therapy Designation from the U.S.
By NAPSRx
Genzyme’s MS therapy, Lemtrada (alemtuzumab) has been approved by the U.S. Food and Drug Administration to treat patients with relapsing forms of multiple sclerosis (MS).
By NAPSRx
The approval of Pfizer's Trumenba represents the first vaccine licensed in the United States to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.
By NAPSRx
Astellas will collaborate with Proteostasis Therapeutics, Inc to develop novel therapeutic contenders that modulate Unfolded Protein Response (UPR) utilizing Proteostasis’ proprietary “Disease Relevant Translation” (DRT™) and “Proteostasis...
By NAPSRx
According to a new study published in the journal Neuropharmacology conducted by research academics at Lancaster University, certain type 2 diabetes drugs on the market have produced neuroprotective effects in a mouse model of Alzheimer's disease.
By NAPSRx
Bristol-Myers Squibb (BMS) has announced their plans to enter into an agreement with F-star Alpha Ltd. giving them the option to obtain the worldwide rights to FS102, a novel Phase 1 ready Human Epidermal growth factor Receptor 2 (HER2)-targeted therapy.
By NAPSRx
In a strategic move to strengthen their vaccine division, Australia’s CSL Ltd will pay Novartis $275 million for their global influenza vaccine business.

All Press Releases

By NAPSRx
The U.S. Food and Drug Administration (FDA) has approved Amgen’s Corlanor® (ivabradine) to treat chronic heart failure.
By NAPSRx
Horizon Pharma plc has announced that ACTIMMUNE® has been granted Fast Track designation from the U.S. Food and Drug Administration (FDA), to treat Friedreich's ataxia (FA), a degenerative neuro-muscular disorder.
By NAPSRx
Bristol-Myers Squibb (BMS) will get exclusive access to uniQure’s gene technology platform based on a strategic collaboration between both companies to identify multiple targets in cardiovascular diseases.
By NAPSRx
ProAir® RespiClick is the first Breath-Actuated Dry-Powder Short-Acting Beta-Agonist (SABA) Inhaler to be approved by the FDA.
By NAPSRx
Jadenu, a new formulation of Exjade (deferasirox) is a simplified daily treatment, administered to patients with chronic iron overload.
By NAPSRx
The U.S. Food and Drug Administration (FDA) has officially greenlighted Regeneron’s EYLEA® (aflibercept) Injection to treat Diabetic Retinopathy in Patients with Diabetic Macular Edema (DME) which marks the fourth approved indication for the drug in...
By NAPSRx
AstraZeneca will enter into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI)  in order to acclimatize a technique for the creation of human beta cells from stem cells for use in screens of AstraZeneca’s compound...
By NAPSRx
Eli Lilly has entered into an exclusive license agreement with Hanmi Pharmaceutical Co., Ltd. to develop and commercialize Hanmi's oral Bruton's tyrosine kinase (BTK) inhibitor, HM71224, for the treatment of autoimmune and other diseases.
By NAPSRx
The Dementia Discovery Fund has been established by the UK government to fuel research and development for Dementia which pose a serious threat to public health and healthcare systems globally according to the World Health Organization.
By NAPSRx
Bayer HealthCare striving for strong sales and margin growth through 2017!
By NAPSRx
The U.S. Food and Drug Administration (FDA) has approved Unituxin (dinutuximab) from the United Therapeutics Corporation as a part of first-line therapy for pediatric patients with high-risk neuroblastoma.
By NAPSRx
In an effort to expand their presence in the oncology market and expand their already resilient pipeline, Abbvie will acquire Pharmacyclics  including its blockbuster product Imbruvica, a first class BTK inhibitor approved for hematologic...
By NAPSRx
The U.S. Food and Drug Administration (FDA) has approved Sanofi’s Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, intended to improve the glycemic index in adults living with type 1 and type 2...
By NAPSRx
Voyager Therapeutics and Genzyme, a Sanofi company, have entered into a  collaborative deal to develop treatments aimed at combatting fatal and debilitating diseases affecting the central nervous system (CNS).
By NAPSRx
Roche’s pharmaceutical division maintained solid sales for the 2014 year as the company revealed a 4% increase in pharmaceutical sales which were primarily driven by medicines in the oncology and immunology segment.
By NAPSRx
The US Food and Drug Administration (FDA) has approved Novartis’ new psoriasis treatment Cosentyx (secukinumab) for adult patients who are candidates for systemic therapy (a drug that is absorbed into the bloodstream and distributed to all parts of the...
By NAPSRx
SAVAYSA™ (edoxaban) tablets, an oral once-daily selective factor Xa-inhibitor have been approved by the U.S.
By NAPSRx
The U.S. Food and Drug Administration has approved Suneva Medical’s dermal filler Bellafill® to treat acne scars.
By NAPSRx
Amgen and Kite Pharma will join forces to develop and commercialize the next generation of novel Chimeric Antigen Receptor (CAR) T cell immunotherapies.
By NAPSRx
Bristol-Myers Squibb Company (NYSE:BMY) and the California Institute for Biomedical Research (Calibr) have announced their plans to collaborate on research and development for small molecule anti-fibrotic treatments.
By NAPSRx
The U.S Food and Drug Administration has greenlighted Novo Nordisk’s new drug application (NDA) for Saxenda®  a once daily once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for adults who are obese (BMI ≥30 kg/m2) or who are...
By NAPSRx
The U.S. Food and Drug Administration has approved Xtoro (finafloxacin otic suspension) to treat acute otitis externa commonly referred to as swimmer's ear.
By NAPSRx
The U.S. Food and Drug Administration has approved Eli Lilly’s Cyramza (ramucirumab) for the treatment of metastatic non-small cell lung cancer (NSCLC) which is the most common type of lung cancer and occurs from cancer cells forming in lung tissue.
By NAPSRx
A new bill has been presented by U.S. Senators Michael Bennet (D-CO) and Orrin Hatch (R-UT)  to develop a new pathway for antibiotic drug approvals called the Promise for Antibiotics and Therapeutics for Health (PATH) Act .This act is anticipated to.
By NAPSRx
In an attempt to accelerate their presence in the antibiotics market, Merck will acquire Cubist Pharmaceuticals for $102 per share in cash- this transaction is expected to amount to $9.5 billion.
By NAPSRx
Eli Lilly will obtain an exclusive worldwide license from Zosano Pharma Corporation to commercialize their investigational therapy ZP-PTH intended to treat osteoporosis patients.
By NAPSRx
AstraZeneca and Eli Lilly and Company have recruited their first patient for the AMARANTH Phase II/III study to assess an oral beta secretase cleaving enzyme (BACE) inhibitor called AZD3293 which is currently being developed as a treatment option for...
By NAPSRx
According to the Decisions Resource Group sales of migraine therapies are projected to grow from $3 billion to over $5 billion in the United States, France, Germany, Italy, Spain, United Kingdom and Japan through 2023.
By NAPSRx
AstraZeneca plans to invest up to $200 million to increase manufacturing and production efforts at its biologics manufacturing center in Frederick, Maryland, US.
By NAPSRx
Sanofi and Regeneron’s investigational therapy, Dupilumab has received the Breakthrough Therapy Designation from the U.S.
By NAPSRx
Genzyme’s MS therapy, Lemtrada (alemtuzumab) has been approved by the U.S. Food and Drug Administration to treat patients with relapsing forms of multiple sclerosis (MS).
By NAPSRx
The approval of Pfizer's Trumenba represents the first vaccine licensed in the United States to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.
By NAPSRx
Astellas will collaborate with Proteostasis Therapeutics, Inc to develop novel therapeutic contenders that modulate Unfolded Protein Response (UPR) utilizing Proteostasis’ proprietary “Disease Relevant Translation” (DRT™) and “Proteostasis...
By NAPSRx
According to a new study published in the journal Neuropharmacology conducted by research academics at Lancaster University, certain type 2 diabetes drugs on the market have produced neuroprotective effects in a mouse model of Alzheimer's disease.
By NAPSRx
Abilify is found to be the preferred brand for the treatment of Schizophrenia according to surveyed U.S. Psychiatrists and Payers
By NAPSRx
Bristol-Myers Squibb (BMS) has announced their plans to enter into an agreement with F-star Alpha Ltd. giving them the option to obtain the worldwide rights to FS102, a novel Phase 1 ready Human Epidermal growth factor Receptor 2 (HER2)-targeted therapy.
By NAPSRx
In a strategic move to strengthen their vaccine division, Australia’s CSL Ltd will pay Novartis $275 million for their global influenza vaccine business.
By NAPSRx
“The approval of this product provides an important therapeutic option for use in the care of patients with this rare disease,” said Karen Midthun, MD, director of FDA’s Center for Biologics Evaluation and Research.
By NAPSRx
Celgene Corporation had a remarkable financial third quarter earning a net income of $508 million for 2014 compared to $372 million in 2013.
By NAPSRx
Johnson & Johnson (NYSE: JNJ) will spend $200 million for further expansion on their Ebola vaccine program at Janssen Pharmaceuticals.
By NAPSRx
The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration (FDA) made a unanimous decision to support the approval of Novartis’ investigational selective interleukin-17A (IL-17A) inhibitor, AIN457...
By NAPSRx
There are many reasons why pharmaceutical sales positions are desired by many aspiring job seekers in the healthcare industry.
By NAPSRx
Roche revealed an impressive financial report for their third quarter with notable sales growth in the pharmaceuticals division.  Group sales were 11.78 billion Swiss francs ( $12.5 billion) up 5% compared to last year.
By NAPSRx
The U.S. Food and Drug Administration has approved two new therapies for the treatment of idiopathic pulmonary fibrosis (IPF) these are Roche’s Esbriet (pirfenidone) and Boehringer Ingelheim’s  OFEV™ (nintedanib*).
By NAPSRx
Astellas Pharma Inc and an investigator at Harvard Medical will collaborate on discovering the pathologic mechanism and identifying therapeutic treatments for retinitis pigmentosa.
By NAPSRx
Johnson & Johnson (NYSE: JNJ) has announced their third quarter earnings for 2014 with sales amounting to $18.5 billion, up 5.1% versus the third quarter of 2013.
By NAPSRx
The United States Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for Pfizer's palbociclib. The NDA submitted requests approval of palbociclib, in combination with letrozole.
By NAPSRx
According to the Decisions Resources Group, the chronic heart failure market will grow from approximately $2.9 billion in 2013 to $8.9 billion in 2023.
By NAPSRx
Benralizumab, AstraZeneca’s novel investigational monoclonal antibody to treat patients with severe, uncontrolled asthma and elevated levels of eosinophils (inflammatory white blood cell)  has produced optimistic safety and efficacy clinical data...
By NAPSRx
Chimerix, Inc. (Nasdaq:CMRX), is a biopharmaceutical company focused on developing and commercializing novel, oral antivirals in areas of high unmet medical need.


Page:

Page updated every 10 minutes


Like PRLog?
9K2K1K
Click to Share